Atrium Therapeutics/$RNA
1D1W1MYTD1Y5YMAX
Capital at risk
About Atrium Therapeutics
Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.
- Ticker
- $RNA
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- -
- Headquarters
- San Diego, United States
- Website
- atriumtherapeutics.com
RNA Metrics
BasicAdvanced
$158M
-
-$3.86
-
-
Price and volume
Market cap
$158M
52-week high
$16.77
52-week low
$8.66
Average daily volume
309K
Financial strength
Current ratio
8.73
Quick ratio
8.376
Total debt to equity
0.008
Profitability
EBITDA (TTM)
-68.528
Gross margin (TTM)
-56.37%
Net profit margin (TTM)
-184.14%
Operating margin (TTM)
-193.13%
Effective tax rate (TTM)
0.21%
Management effectiveness
Valuation
Price to revenue (TTM)
4.401
Price to book
0.74
Price to tangible book (TTM)
0.74
Price to free cash flow (TTM)
-2.791
Free cash flow yield (TTM)
-35.82%
Free cash flow per share (TTM)
-3.303
Growth
Upcoming events
No upcoming events
Funds containing RNA
Fund name | Fund size | $RNA weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.